Online citations, reference lists, and bibliographies.
← Back to Search

Differential Interaction Of Human Renal P-glycoprotein With Various Metabolites And Analogues Of Cyclosporin A.

J. Charuk, P. Y. Wong, R. Reithmeier
Published 1995 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Interactions of P-glycoprotein with several analogues and metabolites of cyclosporin A were studied to gain a better understanding of this immunosuppressant's mechanism of excretion and nephrotoxicity. Incorporation of [3H]azidopine into human renal P-glycoprotein in the presence of various concentrations of different cyclosporins was quantitated. Competitive [3H]azidopine photolabeling and 3H drug transport assays of CHRC5 multidrug-resistant cells were also conducted to evaluate effects of cyclosporins on P-glycoprotein function. Cyclosporins A [half-maximal inhibition constant (K0.5) = 20 nM] and G (K0.5 = 40 nM) blocked [3H]azidopine photolabeling of renal P-glycoprotein at very low concentrations, whereas higher concentrations of cyclosporin C (K0.5 = 500 nM) and metabolites 1, 17, and 21 (K0.5 = 200 nM) were required to inhibit photolabeling. Metabolites H and 8 were ineffective in inhibition of [3H]azidopine photolabeling of human renal P-glycoprotein. Similarly, cyclosporins A, C, and G were the best inhibitors of [3H]azidopine photolabeling of P-glycoprotein in multidrug-resistant C5 cells; the various metabolites were less effective. Cyclosporins A, C, and G also enhanced cellular accumulation of [3H]cyclosporin A and several other 3H-labeled compounds known to be transported by P-glycoprotein in multidrug-resistant C5 cells. Differential affinities of cyclosporin A metabolites for P-glycoprotein suggest considerable drug-binding site specificity. Our current hypothesis is that cyclosporin A may be more nephrotoxic than its metabolites by virtue of its superior ability to bind to and competitively inhibit urinary excretion of an endogenous P-glycoprotein substrate. Our findings provide the basis for future design and testing of new cyclosporin derivatives that have immunosuppressive activity yet may be less nephrotoxic because of their poor interaction with renal P-glycoprotein.



This paper is referenced by
10.1097/FTD.0b013e3181e44244
The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity
D. Hesselink (2010)
10.1016/j.ijpharm.2009.12.040
Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.
Z. Rahman (2010)
10.2165/00003088-199834050-00004
Drug Interactions at the Renal Level
P. Bonate (1998)
10.1023/A:1023481418576
Human Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2 Cells
Yu-Yuan Chiu (2004)
10.1080/03639040500388573
Enhancing the Bioavailability of Cyclosporine A Using Solid Dispersion Containing Polyoxyethylene (40) Stearate
C. Liu (2006)
10.1002/PSC.66
Current Concepts in Intestinal Peptide Absorption
G. Fricker (1996)
10.1152/ajprenal.1998.274.6.F1127
Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine.
J. Charuk (1998)
10.1128/AAC.44.9.2431-2434.2000
Nonylphenolethoxylates as Malarial Chloroquine Resistance Reversal Agents
I. Crandall (2000)
10.1002/JPS.1108
Influence of P-glycoprotein on the transplacental passage of cyclosporine.
P. Pávek (2001)
10.1152/ajprenal.1998.274.6.F1127
Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine.
M. H. Charuk (1998)
10.1038/bjc.1997.127
Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
G. Toffoli (1997)
Impact of ABC transporters on secondary fungal metabolites as remedies or toxins
Tarik Becic (2014)
10.1016/j.chemphyslip.2012.01.007
Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds.
Anna Elgart (2012)
10.1016/S0169-409X(97)00502-4
Renal secretion of xenobiotics mediated by P-glycoprotein: Importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease
N. Simmons (1997)
10.1038/sj.bjp.0702020
Biphasic effects of cyclosporin A on formyl‐methionyl‐leucyl‐phenylalanine stimulated responses in HL‐60 cells differentiated into neutrophils
N. S. Nguyen (1998)
10.1016/J.EJPB.2007.07.006
Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
R. Mueller (2008)
Individualization of Immunosuppressive Therapy after Solid Organ Transplantation
Rachida Bouamar (2014)
10.1002/(SICI)1097-0215(19970529)71:5<900::AID-IJC32>3.0.CO;2-8
Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug‐resistant cells
G. Toffoli (1997)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.2215/CJN.04800908
Calcineurin inhibitor nephrotoxicity.
M. Naesens (2009)
Semantic Scholar Logo Some data provided by SemanticScholar